-- Vudalimab was generally well-tolerated; objective responses observed across multiple tumor types -- -- Confirmed partial responses observed in two of four evaluable castration-resistant prostate cancer patients with measurable disease -- -- Additional complete response observed in patient with

-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 8, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases,

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 4, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that updated clinical data from its Phase 1

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 3, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated clinical data from a Phase 1 study of

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 2, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in the

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 1, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release third quarter 2021 financial

-- Second agreement with Janssen on bispecific antibodies directed toward the CD28 co-stimulatory receptor on T cells -- -- Xencor to receive $100 million upfront payment and $25 million equity investment and is eligible for a mid-teen to low-twenties percent royalty for plamotamab and potential

MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 1, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced five poster presentations at the 36th Annual

MONROVIA, Calif. --(BUSINESS WIRE)--Sep. 20, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the

-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Aug. 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases,